Wan Ping, Yan Min, Yan Chao, Bi Ren-da, Li Chen
Department of Surgery, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2012 Feb;15(2):193-6.
In recent years, based on the phase III clinical study, postoperative chemoradiation, perioperative chemotherapy with ECF regimen and postoperative adjuvant chemotherapy with oral S-1 have become the standard adjuvant treatment of resectable gastric adenocarcinoma in the United States, Europe, and Japan, respectively. Since the Southwest Oncology Group in 2001 reported a large phase III randomized clinical trial INT0116, adjuvant chemoradiotherapy has become a standard treatment for gastric adenocarcinoma. With the rapid development of chemoradiotherapy technique, clinical researches for using operation combined with chemoradiotherapy to treat gastric adenocarcinoma emerged one after another, including adjuvant postoperative chemoradiation, preoperative chemoradiation, and chemoradiation combined with intraoperative radiotherapy and so on. This review will summarize the recent treatment protocol using chemoradiotherapy for resectable gastric adenocarcinoma, and comprehensively evaluate the clinical value and significance of chemoradiotherapy for resectable gastric adenocarcinoma.
近年来，基于III期临床研究，术后放化疗、采用ECF方案的围手术期化疗以及口服S-1的术后辅助化疗分别成为美国、欧洲和日本可切除胃腺癌的标准辅助治疗方法。自2001年西南肿瘤协作组报道了一项大型III期随机临床试验INT0116以来，辅助放化疗已成为胃腺癌的标准治疗方法。随着放化疗技术的迅速发展，采用手术联合放化疗治疗胃腺癌的临床研究相继出现，包括术后辅助放化疗、术前放化疗以及放化疗联合术中放疗等。本综述将总结近期采用放化疗治疗可切除胃腺癌的治疗方案，并全面评估放化疗对可切除胃腺癌的临床价值和意义。
